Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175986 | 0.94 | ESR2 (0.68) | ESR1ESR2AKR1C3HRH3HSD17B3 | |
| SCHEMBL23589286 | 0.86 | HDAC1 (0.51) | ESR1ESR2AKR1C3HRH3HSD17B3 | |
| SCHEMBL22543772 | 0.82 | ESR1 (0.60) | ESR1ESR2AKR1C3HRH3CA7 | |
| SCHEMBL31287276 | 0.82 | ESR1 (0.54) | ESR1ESR2AKR1C3HRH3KDM2B | |
| SCHEMBL22469099 | 0.82 | ESR1 (0.54) | ESR1ESR2AKR1C3HRH3KDM2B | |
| SCHEMBL4137572 | 0.81 | ESR1 (0.59) | ESR1ESR2AKR1C3HRH3CA7 | |
| SCHEMBL3181883 | 0.81 | ESR2 (0.88) | ESR1ESR2AKR1C3HRH3KDM2B | |
| SCHEMBL1265840 | 0.81 | ESR1 (0.59) | ESR1ESR2AKR1C3HRH3CA7 | |
| SCHEMBL1265548 | 0.81 | ESR1 (0.63) | ESR1ESR2AKR1C3HRH3CA7 | |
| SCHEMBL30534601 | 0.81 | ESR1 (0.59) | ESR1ESR2AKR1C3HRH3CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101346353-B | Sulfonamide derivatives and their use in modulating metalloproteases | SERONO LAB | 2012-01-11 | — | — | CN | disclosed |
| EP-1951674-B1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | MERCK SERONO SA (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-1951674-B1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | MERCK SERONO SA (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| CN-101346353-A | Sulfonamide derivatives and their use in modulating metalloproteases | SERONO LAB (CH) | 2009-01-14 | — | — | CN | disclosed |
| EP-1951674-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048788-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007048788-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | MMP12, STS, MMP14 | ESR1 2869/4885ESR2 1013/4885AKR1C3 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.